Advanced search
Publication Cover
Future Medicinal Chemistry Volume 6, 2014 - Issue 7
Submit an article Journal homepage
318
Views
0
CrossRef citations to date
0
Altmetric
Review

Novel DPP-4 Inhibitors Against Diabetes

Yang Liu1 Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, ChinaView further author information
&
Yongzhou Hu1 Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, ChinaCorrespondence[email protected]
View further author information
Pages 793-808 | Published online: 19 Jun 2014

References

  • World Health Organization. www.who.int/diabetes/facts/world_figures/en
  • International Diabetes Federation. Diabetes Atlas. www.eatlas.idf.org
  • Mizuno CS , ChittiboyinaAG, KurtzTWet al. Type 2 diabetes and oral antihyperglycemic drugs. Curr. Med. Chem.15 (1), 61–74 (2008).
  • Stein SA , LamosEM, DavisSN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin. Drug. Saf.12 (2), 153–175 (2013).
  • Drucker DJ . Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Invest. Drugs.12 (1), 87–100 (2003).
  • Weber AE . Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem.47 (17), 4135–4141 (2004).
  • Deacon CF , AhrenB, HolstJJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes?Expert Opin. Investig. Drugs.13 (9), 1091–1102 (2004).
  • Demuth HU , McIntosh, CH, PedersonRA. Type 2 diabetes–therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta.1751 (1), 33–44 (2005).
  • Barnett A . DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract.60 (11), 1454–1470 (2006).
  • Sebokova E , ChristAD, BoehringerMet al. Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr. Top. Med. Chem.7 (6), 547–555 (2007).
  • Hunziker D , HennigM, PetersJU. Inhibitors of dipeptidyl peptidase IV – recent advances and structural views. Curr. Top. Med. Chem.5 (16), 1623–1637 (2005).
  • Gwaltney SL , StaffordJA. Inhibitors of dipeptidyl peptidase 4. Annu. Rep. Med. Chem.40, 149–165 (2005).
  • Wiedeman PE . DPPIV inhibition: promising therapy for the treatment of type 2 diabetes. Prog. Med. Chem.45, 63–109 (2007).
  • Gwaltney SL . Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. Curr. Top. Med. Chem.8 (17), 1545–1552 (2008).
  • Pei Z . From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr. Opin. Drug Discov. Devel.11 (4), 512–532 (2008).
  • Salvatore T , CarbonaraO, CozzolinoDet al. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors. Curr. Diabetes Rev.5 (2), 92–101 (2009).
  • Havale SH , PalM. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg. Med. Chem.17 (5), 1783–1802 (2009).
  • Gupta R , WalunjSS, TokalaRKet al. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 diabetes. Curr. Drug Targets10 (1), 71–87 (2009).
  • Weber AE , ThornberryNA. Dipeptidyl peptidase 4 inhibitors. In: Burger's Medicinal Chemistry, Drug Discovery, and Development (Seventh Edition).Wiley & Sons. NY, USA, 1–38 (2010).
  • Chen SJ , JiaangWT. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein. Curr. Top. Med. Chem.11 (12), 1447–1463 (2011).
  • Liu Y , HuY, LiuT. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. Curr. Med. Chem.19 (23), 3982–3999 (2012).
  • Ghate M , JainSV. Structure based lead optimization approach in discovery of selective DPP4 inhibitors. Mini-Rev. Med. Chem.13 (6), 888–914 (2013).
  • Juillerat-Jeanneret L . Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?J. Med. Chem.57 (6), 2197–2212 (2014). 
  • Lambeir AM , DurinxC, ScharpeSet al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci.40 (3), 209–294 (2003).
  • Rasmussen HB , BrannerS, WibergFCet al. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol.10 (1), 19–25 (2003).
  • Reinhold D , KähneT, SteinbrecherAet al. The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol. Chem.383 (7–8), 1133–1138 (2002).
  • Yu DMT , YaoTW, ChowdhurySet al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J.277 (5), 1126–1144 (2010).
  • Mentlein R , GallwitzB, SchmidtWE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem.214 (3), 829–835 (1993).
  • Marguet D , BaggioL, KobayashiTet al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl Acad. Sci. USA97 (12), 6874–6879 (2000).
  • Kieffer TJ , HabenerJF. The glucagon-like peptides. Endocr. Rev.20 (6), 876–913 (1999).
  • Kuhn B , HennigM, MatteiP. Molecular recognition of ligands in dipeptidyl peptidase IV. Curr. Top. Med. Chem.7 (6), 609–619 (2007).
  • Zettl H , Schubert-ZsilaveczM, SteinhilberD. Medicinal chemistry of incretin mimetics and DPP-4 inhibitors. ChemMedChem5 (2), 179–185 (2010).
  • Chen T , AjamiK, McCaughanGWet al. Dipeptidyl peptidase IV gene family. The DPIV family. Adv. Exp. Med. Biol.524, 79–86 (2003).
  • Lankas GR , LeitingB, RoyRSet al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes54 (10), 2988–2994 (2005).
  • Chiravuri M , SchmitzT, YardleyKet al. A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J. Immunol.163 (6), 3092–3099 (1999).
  • Burkey BF , HoffmannPK, HassiepenUet al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes. Obes. Metab.10 (11), 1057–1061 (2008).
  • ClinicalTrials.gov. http://clinicaltrials.gov
  • Villhauer EB , BrinkmanJA, NaderiGBet al. 1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem.45 (12), 2362–2365 (2002).
  • Villhauer EB , BrinkmanJA, NaderiGBet al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem.46 (13), 2774–2789 (2003).
  • Brandt I , JoossensJ, ChenXet al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem. Pharmacol.70 (1), 134–143 (2005).
  • Stamataros G , SchneiderSH. Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin. Pharmacother.12 (12), 1967–1973 (2011).
  • Scheen AJ . A review of gliptins in 2011. Expert Opin. Pharmacother.13 (1), 81–99 (2012).
  • Cho TP , GangLZ, LongYFet al. Synthesis and biological evaluation of bicyclo[3.3.0]octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett.20 (12), 3521–3525 (2010).
  • Thomas A : WO2006040625 (2006).
  • Madar DJ , KopeckaH, PirehDet al. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. J. Med. Chem.49 (21), 6416–6420 (2006).
  • Fukushima H , HiratateA, TakahashiMet al. Synthesis and structure–activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem.16 (7), 4093–4106 (2008).
  • Kato N , OkaM, MuraseTet al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg. Med. Chem.19 (23), 7221–7227 (2011).
  • Ashworth DM , AtrashB, BakerGRet al. 2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett.6 (10), 1163–1166 (1996).
  • Hulin B , CabralS, LopazeMGet al. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.15 (21), 4770–4773 (2005).
  • Caldwell CG , ChenP, HeJet al. Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.14 (5), 1265–1268 (2004).
  • Augustyns KJL , LambeirAM, BorlooMet al. Pyrrolidides: synthesis and structure–activity relationship as inhibitors of dipeptidyl peptidase IV. Eur. J. Med. Chem.32 (4), 301–309 (1997).
  • Magnin DR , RoblJA, SulskyRBet al. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors. J. Med. Chem.47 (10), 2587–2598 (2004).
  • Augeri DJ , RoblJA, BetebennerDAet al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem.48 (15), 5025–5037 (2005).
  • Thareja S , AggarwalS, MallaPet al. Saxagliptin: a new drug for the treatment of type 2 diabetes. Mini-Rev. Med. Chem.10 (8), 759–765 (2010).
  • Zhao G , KwonC, WangAet al. Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.23 (6), 1622–1625 (2013).
  • Sakashita H , KitajimaH, NakamuraMet al. 1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. Bioorg. Med. Chem. Lett.15 (10), 2441–2445 (2005).
  • Kondo T , NekadoT, SugimotoIet al. Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration. Bioorg. Med. Chem.15 (7), 2631–2650 (2007).
  • Kondo T , NekadoT, SugimotoIet al. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg. Med. Chem.16 (4), 1613–1631 (2008).
  • Ammirati MJ , AndrewsKM, BoyerDDet al. (3,3-difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorg. Med. Chem. Lett.19 (7), 1991–1995 (2009).
  • Fukuda-Tsuru S , AnabukiJ, AbeYet al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur. J. Pharmacol.696 (1–3), 194–202 (2012).
  • Yoshida T , AkahoshiF, SakashitaHet al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem.20 (19), 5705–5719 (2012).
  • Goda M , KadowakiT. Teneligliptin for the treatment of Type 2 diabetes. Drug. Today.49 (10), 615–629 (2013).
  • Xu J , WeiL, MathvinkRet al. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.15 (10), 2533–2536 (2005).
  • Liang GB , QianX, FengDet al. Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett.17 (7), 1903–1907 (2007).
  • Biftu T , FengD, QianXet al. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett.17 (1), 49–52 (2007).
  • Nitta A , FujiiH, SakamiSet al. (3R)-3-Amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett.18 (20), 5435–5438 (2008).
  • Nitta A , FujiiH, SakamiSet al. Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.22 (23), 7036–7040 (2012).
  • Pei Z , LiX, von GeldernTWet al. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem.49 (22), 6439–6442 (2006).
  • Lam B , ZhangZ, StaffordJAet al. Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.22 (21), 6628–6631 (2012).
  • Jun MA , ParkWS, KangSKet al. Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors. Eur. J. Med. Chem.43 (9), 1889–1902 (2008).
  • Kim HJ , KwakWY, MinJPet al. Dipeptidyl peptidase-4 inhibitor with beta-amino amide scaffold: synthesis, SAR and biological evaluation. Bioorg. Med. Chem. Lett.22 (17), 5545–5549 (2012).
  • Ahn JH , ShinMS, JunMAet al. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg. Med. Chem. Lett.17 (9), 2622–2628 (2007).
  • Ahn JH , ParkWS, JunMAet al. Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.18 (24), 6525–6529 (2008).
  • Cox JM , HarperB, MastracchioAet al. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.17 (16), 4579–4583 (2007).
  • Edmondson SD , MastracchioA, CoxJMet al. Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg. Med. Chem. Lett.19 (15), 4097–4101 (2009).
  • Biftu T , ScapinG, SinghSet al. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Bioorg. Med. Chem. Lett.17 (12), 3384–3387 (2007).
  • Biftu T , QianX, ChenPet al. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23). Bioorg. Med. Chem. Lett.23 (19), 5361–5366 (2013).
  • Brunavs M , CowleyP, WardSWet al. Recent disclosures of clinical candidates (SMR Award Lecture)-highlights from the society for medicines research symposium, held on December 5th 2012 at the national heart & lung institute (NHLI), London, UK. Drugs Fut.38 (2), 127–133 (2013).
  • Peters JU , HunzikerD, FischerHet al. An aminomethylpyrimidine DPP-IV inhibitor with improved properties. Bioorg. Med. Chem. Lett.14 (13), 3575–3578 (2004).
  • Brigance RP , MengW, FuraAet al. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes. Bioorg. Med. Chem. Lett.20 (15), 4395–4398 (2010).
  • Meng W , BriganceRP, ChaoHJet al. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2- carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J. Med. Chem.53 (15), 5620–5628 (2010).
  • Eckhardt M , LangkopfE, MarkMet al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin -2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem.50 (26), 6450–6453 (2007).
  • Rungby J . Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes. Expert Opin. Invest. Drugs18 (6), 835–838 (2009).
  • Baetta R , CorsiniA. Pharmacology of dipeptidyl peptidase-4 inhibitors similarities and differences. Drugs71 (11), 1441–1467 (2011).
  • Huttner S , Graefe-ModyEU, WithopfBet al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J. Clin. Pharmacol.48 (10), 1171–1178 (2008).
  • Agrawal R , JainP, DikshitSN. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor. Curr. Drug. Targets.13 (7), 970–983 (2012).
  • Nishio Y , KimuraH, SawadaNet al. 2-({6-[(3R)-3-Amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3, 4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A. Bioorg. Med. Chem.19 (18), 5490–5499 (2011).
  • Brockunier LL , HeJ, ColwellLFet al. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett.14 (18), 4763–4766 (2004).
  • Thornberry NA , WeberAE. Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem.7 (6), 557–568 (2007).
  • Kim D , WangL, BeconiMet al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem.48 (1), 141–151 (2005).
  • Kim D , KowalchickJE, EdmondsonSDet al. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). Bioorg. Med. Chem. Lett.17 (12), 3373–3377 (2007).
  • Kim D , KowalchickJE, BrockunierLLet al. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines. J. Med. Chem.51 (3), 589–602 (2008).
  • Deacon CF . Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin. Invest. Drugs16 (4), 533–545 (2007).
  • Nordhoff S , Cerezo-GalvezS, FeurerAet al. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: x-ray structures and properties of novel fragment and elaborated inhibitors. Bioorg. Med. Chem. Lett.16 (6), 1744–1748 (2006).
  • Nordhoff S , Cerezo-GalvezS, DeppeHet al. Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett.19 (15), 4201–4203 (2009).
  • Nordhoff S , Lopez-CanetM, Hoffmann-EngerBet al. From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett.19 (16), 4818–4823 (2009).
  • Nordhoff S , BulatS, Cerezo-GalvezSet al. The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements. Bioorg. Med. Chem. Lett.19 (22), 6340–6345 (2009).
  • Wright SW , AmmiratiMJ, AndrewsKMet al. (3R,4S)-4-(2,4,5-trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and x-ray crystallographic characterization. Bioorg. Med. Chem. Lett.17 (20), 5638–5642 (2007).
  • Andrews KM , BeebeDA, BenbowJWet al. 1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett.21 (6), 1810–1814 (2011).
  • Feng J , ZhangZ, WallaceMBet al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem.50 (10), 2297–2300 (2007).
  • Deng J , PengL, ZhangGet al. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. Eur. J. Med. Chem.46 (1), 71–76 (2011).
  • Xie H , ZengL, ZengSet al. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. Eur. J. Med. Chem.52, 205–212 (2012).
  • Zhang Z , WallaceMB, FengJet al. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J. Med. Chem.54 (2), 510–524 (2011).
  • Parsa KV , PalM. Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. Expert Opin. Drug Discov.6 (8), 855–869 (2011).
  • Deacon CF . Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr. Opin. Invest. Drugs9 (4), 402–413 (2008).
  • Agrawal R , BahareRS, JainPet al. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin. Mini-Rev. Med Chem.12 (13), 1345–1358 (2012).
  • Capuano A , SportielloL, MaiorinoMIet al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy-focus on alogliptin. Drug Des. Devel. Ther.7, 989–1001 (2013).
  • DeFronzo RA , FleckPR, WilsonCAet al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care31 (12), 2315–2317 (2008).
  • Cahn A , RazI. Emerging gliptins for type 2 diabetes. Expert Opin. Emerg. Drugs18 (2), 245–258 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.